Values as of: 2025-01-08
COMMON STOCK | Medical Devices |
Last Closing
USD 0.48Change
+0.01 (+2.13)%Market Cap
USD 0.03BVolume
0.07MAnalyst Target
N/AVerdict
Verdict
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L spinal fusion system. The company was founded in 2013 and is headquartered in Toronto, Canada.
Company Website : https://www.aurora-spine.com
Currency: CAD
Country : Canada
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| TLT:CA | Theralase Technologies Inc. |
-0.01 (-1.64%) |
USD 0.07B |
| PINK:CA | Perimeter Medical Imaging AI I.. |
+0.03 (+6.02%) |
USD 0.05B |
| MDX:CA | MedX Health Corp |
N/A |
USD 0.02B |
| NGMD:CA | NuGen Medical Devices Inc |
N/A |
USD 0.02B |
| VPT:CA | VentriPoint Diagnostics Ltd |
+0.01 (+4.76%) |
USD 0.02B |
| THRM:CA | Therma Bright Inc |
-0.01 (-12.50%) |
USD 0.01B |
| EVMT:CA | Evome Medical Technologies Inc.. |
+0.01 (+3.45%) |
USD 0.01B |
| FREQ:CA | Frequency Exchange Corp. |
N/A |
USD 0.01B |
| CNVI:CA | Conavi Medical Corp. |
-0.05 (-7.35%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 23.08% | 100% | F | 79% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 23.08% | 100% | F | 79% | B- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 33.33% | 75% | C | 75% | C | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 33.33% | 75% | C | 75% | C | ||
| Trailing 5 Years | |||||||
| Capital Gain | 92.00% | 80% | B- | 83% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 92.00% | 80% | B- | 82% | B | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 32.68% | 75% | C | 77% | C+ | ||
| Dividend Return | 32.68% | 75% | C | 77% | C+ | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 106.20% | 38% | F | 28% | F | ||
| Risk Adjusted Return | 30.77% | 75% | C | 80% | B- | ||
| Market Capitalization | 0.03B | 78% | C+ | 80% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
